GlobalData on MSN8h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.
Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...
At medical conferences and hospital cafeterias, one thing has become increasingly clear—many doctors are using Ozempic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback